MIRUM PHARMACEUTICALS INC
NASDAQ: MIRM (Mirum Pharmaceuticals, Inc.)
Kemas kini terakhir: 2 hari lalu, 4:38PM44.46
0.46 (1.05%)
Penutupan Terdahulu | 44.00 |
Buka | 43.85 |
Jumlah Dagangan | 289,888 |
Purata Dagangan (3B) | 446,237 |
Modal Pasaran | 2,202,312,704 |
Harga / Pendapatan (P/E Ke hadapan) | 39.68 |
Harga / Jualan (P/S) | 5.57 |
Harga / Buku (P/B) | 9.34 |
Julat 52 Minggu | |
Tarikh Pendapatan | 6 Aug 2025 |
Margin Keuntungan | -20.39% |
Margin Operasi (TTM) | -13.61% |
EPS Cair (TTM) | -1.61 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 61.20% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 135.97% |
Nisbah Semasa (MRQ) | 3.22 |
Aliran Tunai Operasi (OCF TTM) | -6.85 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -23.97 M |
Pulangan Atas Aset (ROA TTM) | -7.11% |
Pulangan Atas Ekuiti (ROE TTM) | -33.06% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Menurun | Menurun |
Biotechnology (Global) | Menurun | Menurun | |
Stok | Mirum Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
Konsensus Penganalisis | 5.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 2.0 |
Purata Bergerak Teknikal | 2.5 |
Osilator Teknikal | 2.5 |
Purata | 3.00 |
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter “IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Small Growth |
% Dimiliki oleh Orang Dalam | 1.98% |
% Dimiliki oleh Institusi | 114.18% |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 77.00 (Raymond James, 73.19%) | Beli |
Median | 76.00 (70.94%) | |
Rendah | 73.00 (HC Wainwright & Co., 64.19%) | Beli |
Purata | 75.33 (69.43%) | |
Jumlah | 3 Beli | |
Harga Purata @ Panggilan | 44.81 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
HC Wainwright & Co. | 19 May 2025 | 73.00 (64.19%) | Beli | 44.89 |
Raymond James | 13 May 2025 | 77.00 (73.19%) | Beli | 45.27 |
JMP Securities | 09 May 2025 | 76.00 (70.94%) | Beli | 44.27 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |